Question 1

What is combined oxidative phosphorylation deficiency 59?

Accepted Answer

Combined oxidative phosphorylation deficiency 59 is a multisystem condition that affects energy production in cells, particularly impacting both the central nervous system and other organs. Variants in the MRPL39 gene, which encodes a mitochondrial ribosomal protein involved in protein synthesis, are responsible for this condition. It is inherited in an autosomal recessive manner, meaning that both parents must carry a variant even though they may show no symptoms themselves. Prevalence estimates are not well established, and affected individuals can present with a broad range of clinical features.

Question 2

What are the symptoms of combined oxidative phosphorylation deficiency 59?

Accepted Answer

The clinical presentation of combined oxidative phosphorylation deficiency 59 involves a range of neurological and systemic features. Characteristic findings include consistently elevated brain lactate levels by MRS and decreased activities of mitochondrial complex IV and complex I, which point to an underlying impairment in cellular energy production. Affected children often exhibit neurodevelopmental challenges such as attention deficit hyperactivity disorder, global developmental delay, and cognitive or behavioral difficulties. After a period of apparently typical early development, affected children experience a phase of developmental regression marked by loss of previously acquired skills, and many also face other challenges including feeding difficulties, vomiting, and migraine. In addition, variable features affecting other organ systems such as hypertrophic cardiomyopathy, congestive heart failure, retinal degeneration, and cholelithiasis may be observed. Not all individuals experience all features, and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation deficiency 59?

Accepted Answer

Combined oxidative phosphorylation deficiency 59 is caused by pathogenic variants in the MRPL39 gene. MRPL39 plays a critical role in mitochondrial protein synthesis, and dysfunction in this protein disrupts the normal energy production process in cells. The condition is inherited in an autosomal recessive pattern, meaning that an affected individual has received one altered copy of the gene from each carrier parent. Families are encouraged to seek genetic counseling to understand the implications of this inheritance pattern for future family planning. Associated genes include MRPL39.

Question 4

How is combined oxidative phosphorylation deficiency 59 inherited?

Accepted Answer

combined oxidative phosphorylation deficiency 59 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How is combined oxidative phosphorylation deficiency 59 diagnosed?

Accepted Answer

Diagnosis of combined oxidative phosphorylation deficiency 59 is confirmed through molecular genetic testing, which identifies pathogenic variants in the MRPL39 gene. In addition to genetic testing, clinical evaluation that considers characteristic features such as elevated brain lactate levels and decreased mitochondrial enzyme activities plays an important role. Because many of these features can be seen in other conditions, molecular genetic testing is essential to confirm the diagnosis and differentiate it from other disorders.

Question 6

Are there treatments for combined oxidative phosphorylation deficiency 59?

Accepted Answer

Currently, management focuses on supportive care and symptom management, with treatment tailored to the needs of each individual. Because there are no FDA-approved treatments specifically linked to this condition, care is provided by a multidisciplinary team experienced in managing multisystem disorders. Regular surveillance is an essential part of long-term care, helping to identify potential complications early, whether they involve cardiac, neurological, or other organ systems. Genetic counseling is recommended to help families understand the condition and to discuss potential treatment strategies with their healthcare team.

Question 7

What are the potential complications of combined oxidative phosphorylation deficiency 59?

Accepted Answer

Individuals with combined oxidative phosphorylation deficiency 59 may face various complications due to the multisystem nature of the condition. These can include cardiac issues like hypertrophic cardiomyopathy and congestive heart failure, as well as neurological challenges. Regular monitoring is important to catch any complications early, especially those affecting the heart and other organs.

Question 8

How does combined oxidative phosphorylation deficiency 59 affect daily life for patients and their families?

Accepted Answer

Living with combined oxidative phosphorylation deficiency 59 can be challenging for both patients and their families. Affected individuals may experience developmental delays and regression, which can impact their daily activities and require additional support. Families often need to work closely with a multidisciplinary team to manage symptoms and ensure the best possible care.

Question 9

What is the long-term prognosis for someone with combined oxidative phosphorylation deficiency 59?

Accepted Answer

The long-term outlook for individuals with combined oxidative phosphorylation deficiency 59 varies widely. Some may experience a phase of developmental regression followed by stabilization, while others could face ongoing challenges or complications. Access to specialized care can significantly influence outcomes, so families are encouraged to connect with experts in managing this condition.

Question 10

What specialists should families consult for managing combined oxidative phosphorylation deficiency 59?

Accepted Answer

Families dealing with combined oxidative phosphorylation deficiency 59 should consult a multidisciplinary team of specialists. This may include neurologists, cardiologists, and genetic counselors who are experienced in managing multisystem disorders. These specialists can help tailor care to the individual's needs and provide guidance on monitoring and treatment options.

Research Type	Count	% of Total
Laboratory research	10	59%

Kisho

combined oxidative phosphorylation deficiency 59

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

combined oxidative phosphorylation deficiency 59

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation deficiency 59?

What are the symptoms of combined oxidative phosphorylation deficiency 59?

What causes combined oxidative phosphorylation deficiency 59?

How is combined oxidative phosphorylation deficiency 59 inherited?

How is combined oxidative phosphorylation deficiency 59 diagnosed?

Are there treatments for combined oxidative phosphorylation deficiency 59?

What are the potential complications of combined oxidative phosphorylation deficiency 59?

How does combined oxidative phosphorylation deficiency 59 affect daily life for patients and their families?

What is the long-term prognosis for someone with combined oxidative phosphorylation deficiency 59?

What specialists should families consult for managing combined oxidative phosphorylation deficiency 59?

Explore clinical features

Recent Publications